Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

Authors: Mala Dharmalingam, S. R. Aravind, Hemant Thacker, S. Paramesh, Brij Mohan, Manoj Chawla, Arthur Asirvatham, Ramesh Goyal, Jayashri Shembalkar, R. Balamurugan, Pradnya Kadam, Hansraj Alva, Rahul Kodgule, Monika Tandon, Sivakumar Vaidyanathan, Amol Pendse, Rajesh Gaikwad, Sagar Katare, Sachin Suryawanshi, Hanmant Barkate

Published: 2020-03-11

DOI: 10.1007/s40265-020-01285-0

Source: Full article

---

Abstract

No abstract found.